カルチノイド腫瘍の世界市場レポート 2025年

カルチノイド腫瘍市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR10.5％で26億5,000万米ドルに成長します。予測期間中の成長は、個別化医療への需要の高まり、早期発見・診断への注目の高まり、低侵襲手術の採用拡大、新規治療法の研究拡大、分子標的治療の利用拡大などに起因すると考えられます。この期間に予想される主な動向には、診断におけるAIと機械学習の統合、併用療法へのシフト、遠隔医療と遠隔モニタリングの拡大、患者中心のケアへの重点化、共同研究活動の増加などがあります。

肥満の増加はカルチノイド腫瘍市場の成長を促進しています。肥満症は、体格指数（BMI）が30以上であることを特徴とし、食生活の乱れ、運動不足、加工食品の過剰摂取などの要因によって増加しています。このような状態は、慢性炎症、インスリン抵抗性、カルチノイド腫瘍を含む腫瘍開発の一因となる成長因子の分泌を促進します。例えば、米国疾病予防管理センター（CDC）によると、2022年には米国の22州で成人の肥満率が35％以上と報告され、2021年の19州から増加しています。肥満率が上昇を続ける中、カルチノイド腫瘍を含む肥満関連がんの発生率も上昇し、市場はさらに拡大すると予想されます。

神経内分泌腫瘍の検出における進歩も市場成長に重要な役割を果たしています。各社は、早期発見を強化し治療成績を向上させるため、全自動のクロモグラニンA（CgA）検査などの革新的な診断ツールを開発しています。2023年10月、サーモフィッシャーサイエンティフィックは、FDAが承認した初のクロモグラニンA検査であるサーモサイエンティフィックB*R*A*H*M*S CgA II KRYPTORイムノアッセイのFDA認可を取得しました。この完全自動化検査は、胃腸膵神経内分泌腫瘍（GEP-NET）患者のCgAレベルを測定し、腫瘍の進行のモニタリングや治療効果の評価に役立ちます。TRACE技術の活用により、この検査は30分以内に正確な結果を提供し、手作業で開発された検査に取って代わり、診断精度と効率を向上させる。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界カルチノイド腫瘍PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のカルチノイド腫瘍市場：成長率分析
• 世界のカルチノイド腫瘍市場の実績：規模と成長, 2019-2024
• 世界のカルチノイド腫瘍市場の予測：規模と成長, 2024-2029, 2034F
• 世界カルチノイド腫瘍総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のカルチノイド腫瘍市場：疾患タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 消化管神経内分泌腫瘍
• 膵神経内分泌腫瘍
• 肺神経内分泌腫瘍
• その他の病気の種類
• 世界のカルチノイド腫瘍市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オクトレオチド
• ランレオチド
• テロトリスタットエチル
• カペシタビン（ゼローダ）
• 5-フルオロウラシル（5-FU）
• ドキソルビシン（アドリアマイシン）
• エトポシド（VP-16）
• ダカルバジン（DTIC）
• ストレプトゾシン
• その他の治療法
• 世界のカルチノイド腫瘍市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 非経口
• その他の投与経路
• 世界のカルチノイド腫瘍市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オンラインチャンネル
• オフラインチャンネル
• 世界のカルチノイド腫瘍市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院と診療所
• 学術機関
• 調査機関
• 世界のカルチノイド腫瘍市場消化管神経内分泌腫瘍の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 小腸神経内分泌腫瘍
• 大腸神経内分泌腫瘍
• 虫垂神経内分泌腫瘍
• 世界のカルチノイド腫瘍市場膵神経内分泌腫瘍の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• インスリノーマ
• 非インスリノーマ
• グルカゴノーマ
• 世界のカルチノイド腫瘍市場肺神経内分泌腫瘍の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 典型的なカルチノイド腫瘍
• 非典型カルチノイド腫瘍
• 世界のカルチノイド腫瘍市場、その他の疾患タイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 胸腺神経内分泌腫瘍
• 卵巣神経内分泌腫瘍

第7章 地域別・国別分析

• 世界のカルチノイド腫瘍市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のカルチノイド腫瘍市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• カルチノイド腫瘍市場：競合情勢
• カルチノイド腫瘍市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Abbott Laboratories
• Novartis AG
• GlaxoSmithKline plc
• Eli Lilly and Company
• Siemens Healthineers AG
• Boston Scientific Corporation
• Boehringer Ingelheim International GmbH
• Catalent Inc
• Ipsen S.A.
• Exelixis Inc
• Novocure Limited
• Hutchison MediPharma Limited（A subsidiary of HUTCHMED）
• Tarveda Therapeutics Inc.
• Lexicon Pharmaceuticals Inc.
• Dauntless Pharmaceuticals Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• カルチノイド腫瘍市場2029：新たな機会を提供する国
• カルチノイド腫瘍市場2029：新たな機会を提供するセグメント
• カルチノイド腫瘍市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

A carcinoid tumor is a rare, slow-growing neuroendocrine tumor that typically develops in the gastrointestinal tract or lungs. It originates from enterochromaffin cells, which produce and release hormones such as serotonin. Symptoms vary depending on the tumor's location and whether it secretes hormones, potentially leading to carcinoid syndrome.

The primary types of carcinoid tumors include gastrointestinal neuroendocrine tumors (GI NETs), pancreatic neuroendocrine tumors, lung neuroendocrine tumors, and other disease types. Gastrointestinal neuroendocrine tumors (GI NETs) arise from neuroendocrine cells in the digestive system, with carcinoid tumors being a common, slow-growing subtype. Treatment options include octreotide, lanreotide, telotristat ethyl, capecitabine (Xeloda), 5-fluorouracil (5-FU), doxorubicin (Adriamycin), etoposide (VP-16), dacarbazine (DTIC), streptozocin, and other therapies, administered via oral and parenteral routes. These treatments are distributed through both online and offline channels and are utilized by hospitals, clinics, academic institutions, and research organizations.

The carcinoid tumor market research report is one of a series of new reports from The Business Research Company that provides carcinoid tumor market statistics, including the carcinoid tumor industry global market size, regional shares, competitors with the carcinoid tumor market share, detailed carcinoid tumor market segments, market trends, and opportunities, and any further data you may need to thrive in the carcinoid tumor industry. This carcinoid tumor market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The carcinoid tumor market size has grown rapidly in recent years. It will grow from $1.61 billion in 2024 to $1.78 billion in 2025 at a compound annual growth rate (CAGR) of 10.7%. The growth during the historic period can be attributed to the rising incidence of neuroendocrine tumors, increased awareness of rare cancers, improvements in healthcare infrastructure, the availability of targeted therapies, and the expansion of clinical trials for new treatment options.

The carcinoid tumor market size is expected to see rapid growth in the next few years. It will grow to $2.65 billion in 2029 at a compound annual growth rate (CAGR) of 10.5%. The growth during the forecast period can be attributed to the rising demand for personalized medicine, a greater focus on early detection and diagnosis, increased adoption of minimally invasive surgeries, expanding research on novel therapies, and the growing use of molecular targeted therapies. Key trends expected in this period include the integration of AI and machine learning in diagnostics, a shift toward combination therapies, the expansion of telemedicine and remote monitoring, a focus on patient-centric care, and increased collaborative research efforts.

The increasing prevalence of obesity is driving the growth of the carcinoid tumor market. Obesity, characterized by a body mass index (BMI) of 30 or higher, is rising due to factors such as poor dietary habits, lack of physical activity, and excessive consumption of processed foods. This condition promotes chronic inflammation, insulin resistance, and the secretion of growth factors that contribute to tumor development, including carcinoid tumors. For example, according to the Centers for Disease Control and Prevention (CDC), in 2022, 22 U.S. states reported an adult obesity rate of 35% or higher, up from 19 states in 2021. As obesity rates continue to rise, the incidence of obesity-related cancers, including carcinoid tumors, is expected to increase, further expanding the market.

Advancements in neuroendocrine tumor detection are also playing a crucial role in market growth. Companies are developing innovative diagnostic tools, such as fully automated chromogranin A (CgA) tests, to enhance early detection and improve treatment outcomes. In October 2023, Thermo Fisher Scientific received FDA clearance for the Thermo Scientific B*R*A*H*M*S CgA II KRYPTOR immunoassay, the first FDA-approved chromogranin A test. This fully automated test measures CgA levels in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs), helping monitor tumor progression and assess treatment efficacy. By utilizing TRACE technology, the test provides precise results in under 30 minutes, replacing manual laboratory-developed tests and improving diagnostic accuracy and efficiency.

In April 2022, SERB Pharmaceuticals acquired the European commercialization rights for Xermelo (telotristat ethyl) from Ipsen. Xermelo is a treatment for carcinoid syndrome diarrhea, a symptom of carcinoid tumors. This acquisition strengthens SERB's portfolio of treatments for rare diseases and expands access to improved therapeutic options outside the U.S. and Japan. Ipsen, a France-based biopharmaceutical company, continues to focus on developing treatments for carcinoid syndrome and other rare cancers, contributing to the overall growth of the market.

Major players in the carcinoid tumor market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Sanofi S.A., Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Siemens Healthineers AG, Boston Scientific Corporation, Boehringer Ingelheim International GmbH, Catalent Inc, Ipsen S.A., Exelixis Inc, Novocure Limited, Hutchison MediPharma Limited (A subsidiary of HUTCHMED), Tarveda Therapeutics Inc., Lexicon Pharmaceuticals Inc., and Dauntless Pharmaceuticals Inc.

North America was the largest region in the carcinoid tumor market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in carcinoid tumor report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the carcinoid tumor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The carcinoid tumor market consists of revenues earned by entities by providing services such as pharmaceutical treatment, radiation therapy, diagnostic services, and surgical interventions. The market value includes the value of related goods sold by the service provider or included within the service offering. The carcinoid tumor market also includes sales of diagnostic tools, pharmaceuticals, chemotherapy agents, radiopharmaceuticals, and supportive care products. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Carcinoid Tumor Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on carcinoid tumor market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for carcinoid tumor ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The carcinoid tumor market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Disease Type: Gastrointestinal Neuroendocrine Tumor; Pancreatic Neuroendocrine Tumor; Lung Neuroendocrine Tumor; Other Disease Types
• 2) By Treatment: Octreotide; Lanreotide; Telotristat ethyl; Capecitabine (Xeloda); 5-Fluorouracil (5-FU); Doxorubicin (Adriamycin); Etoposide (VP-16); Dacarbazine (DTIC); Streptozocin; Other Treatments
• 3) By Route Of Administration: Oral; Parenteral; Other Routes Of Administration
• 4) By Distribution Channel: Online Channel; Offline Channel
• 5) By End User: Hospital And Clinics; Academic Institutions; Research Organizations
• Subsegments:
• 1) By Gastrointestinal Neuroendocrine Tumor: Small Bowel Neuroendocrine Tumors; Colorectal Neuroendocrine Tumors; Appendiceal Neuroendocrine Tumors
• 2) By Pancreatic Neuroendocrine Tumor: Insulinoma; Non-insulinoma; Glucagonoma
• 3) By Lung Neuroendocrine Tumor: Typical Carcinoid Tumors; Atypical Carcinoid Tumors
• 4) By Other Disease Types: Thymic Neuroendocrine Tumors; Ovarian Neuroendocrine Tumors
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; Sanofi S.A.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Carcinoid Tumor Market Characteristics

3. Carcinoid Tumor Market Trends And Strategies

4. Carcinoid Tumor Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Carcinoid Tumor Growth Analysis And Strategic Analysis Framework

• 5.1. Global Carcinoid Tumor PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Carcinoid Tumor Market Growth Rate Analysis
• 5.4. Global Carcinoid Tumor Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Carcinoid Tumor Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Carcinoid Tumor Total Addressable Market (TAM)

6. Carcinoid Tumor Market Segmentation

• 6.1. Global Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Gastrointestinal Neuroendocrine Tumor
• Pancreatic Neuroendocrine Tumor
• Lung Neuroendocrine Tumor
• Other Disease Types
• 6.2. Global Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Octreotide
• Lanreotide
• Telotristat ethyl
• Capecitabine (Xeloda)
• 5-Fluorouracil (5-FU)
• Doxorubicin (Adriamycin)
• Etoposide (VP-16)
• Dacarbazine (DTIC)
• Streptozocin
• Other Treatments
• 6.3. Global Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• Other Routes Of Administration
• 6.4. Global Carcinoid Tumor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Online Channel
• Offline Channel
• 6.5. Global Carcinoid Tumor Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital And Clinics
• Academic Institutions
• Research Organizations
• 6.6. Global Carcinoid Tumor Market, Sub-Segmentation Of Gastrointestinal Neuroendocrine Tumor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Small Bowel Neuroendocrine Tumors
• Colorectal Neuroendocrine Tumors
• Appendiceal Neuroendocrine Tumors
• 6.7. Global Carcinoid Tumor Market, Sub-Segmentation Of Pancreatic Neuroendocrine Tumor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Insulinoma
• Non-insulinoma
• Glucagonoma
• 6.8. Global Carcinoid Tumor Market, Sub-Segmentation Of Lung Neuroendocrine Tumor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Typical Carcinoid Tumors
• Atypical Carcinoid Tumors
• 6.9. Global Carcinoid Tumor Market, Sub-Segmentation Of Other Disease Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Thymic Neuroendocrine Tumors
• Ovarian Neuroendocrine Tumors

7. Carcinoid Tumor Market Regional And Country Analysis

• 7.1. Global Carcinoid Tumor Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Carcinoid Tumor Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Carcinoid Tumor Market

• 8.1. Asia-Pacific Carcinoid Tumor Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Carcinoid Tumor Market

• 9.1. China Carcinoid Tumor Market Overview
• 9.2. China Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Carcinoid Tumor Market

• 10.1. India Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Carcinoid Tumor Market

• 11.1. Japan Carcinoid Tumor Market Overview
• 11.2. Japan Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Carcinoid Tumor Market

• 12.1. Australia Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Carcinoid Tumor Market

• 13.1. Indonesia Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Carcinoid Tumor Market

• 14.1. South Korea Carcinoid Tumor Market Overview
• 14.2. South Korea Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Carcinoid Tumor Market

• 15.1. Western Europe Carcinoid Tumor Market Overview
• 15.2. Western Europe Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Carcinoid Tumor Market

• 16.1. UK Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Carcinoid Tumor Market

• 17.1. Germany Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Carcinoid Tumor Market

• 18.1. France Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Carcinoid Tumor Market

• 19.1. Italy Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Carcinoid Tumor Market

• 20.1. Spain Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Carcinoid Tumor Market

• 21.1. Eastern Europe Carcinoid Tumor Market Overview
• 21.2. Eastern Europe Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Carcinoid Tumor Market

• 22.1. Russia Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Carcinoid Tumor Market

• 23.1. North America Carcinoid Tumor Market Overview
• 23.2. North America Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Carcinoid Tumor Market

• 24.1. USA Carcinoid Tumor Market Overview
• 24.2. USA Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Carcinoid Tumor Market

• 25.1. Canada Carcinoid Tumor Market Overview
• 25.2. Canada Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Carcinoid Tumor Market

• 26.1. South America Carcinoid Tumor Market Overview
• 26.2. South America Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Carcinoid Tumor Market

• 27.1. Brazil Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Carcinoid Tumor Market

• 28.1. Middle East Carcinoid Tumor Market Overview
• 28.2. Middle East Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Carcinoid Tumor Market

• 29.1. Africa Carcinoid Tumor Market Overview
• 29.2. Africa Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Carcinoid Tumor Market Competitive Landscape And Company Profiles

• 30.1. Carcinoid Tumor Market Competitive Landscape
• 30.2. Carcinoid Tumor Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

31. Carcinoid Tumor Market Other Major And Innovative Companies

• 31.1. Abbott Laboratories
• 31.2. Novartis AG
• 31.3. GlaxoSmithKline plc
• 31.4. Eli Lilly and Company
• 31.5. Siemens Healthineers AG
• 31.6. Boston Scientific Corporation
• 31.7. Boehringer Ingelheim International GmbH
• 31.8. Catalent Inc
• 31.9. Ipsen S.A.
• 31.10. Exelixis Inc
• 31.11. Novocure Limited
• 31.12. Hutchison MediPharma Limited (A subsidiary of HUTCHMED)
• 31.13. Tarveda Therapeutics Inc.
• 31.14. Lexicon Pharmaceuticals Inc.
• 31.15. Dauntless Pharmaceuticals Inc.

32. Global Carcinoid Tumor Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Carcinoid Tumor Market

34. Recent Developments In The Carcinoid Tumor Market

35. Carcinoid Tumor Market High Potential Countries, Segments and Strategies

• 35.1 Carcinoid Tumor Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Carcinoid Tumor Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Carcinoid Tumor Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer